UK children recruited for H1N1 vaccine trials

pharmafile | October 2, 2009 | News story | Research and Development, Sales and Marketing h1n1, paediatric, vaccines 

The UK has commenced a two-week swine flu vaccine trial, a month ahead of its planned programme to vaccinate 11 million people in the country.

Doctors at five sites in England will compare vaccines from two manufacturers to see which vaccine works best and has the fewest side-effects.

One thousand children aged six months to 12 years are expected to be recruited onto the trials in Oxford, Bristol, Southampton, Exeter and London.

European regulators recently licensed the first two swine flu vaccines, GlaxoSmithKline's Pandemrix and Novartis' Focetria.

Professor Andrew Pollard, from the University of Oxford told the BBC that vaccines are the best way to protect against flu and any side effects should be limited to sore arms or sometimes a fever.

The UK programme will initially vaccinate the people considered those most at risk from swine flu.

The vaccine will also be made available to more than two million front-line health workers.


Related Content

Janssen and Sanofi enter agreement for potential vaccine programme

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …


Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine

Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

The University of Birmingham hosted Bacterial Vaccines Network has been awarded £1.4m in funding from …

Latest content